GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosolution Co Ltd (XKRX:086820) » Definitions » Debt-to-EBITDA

Biosolution Co (XKRX:086820) Debt-to-EBITDA : -1.73 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Biosolution Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Biosolution Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩27,268 Mil. Biosolution Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩971 Mil. Biosolution Co's annualized EBITDA for the quarter that ended in Dec. 2024 was ₩-16,364 Mil. Biosolution Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -1.73.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Biosolution Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:086820' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.34   Med: 4.34   Max: 34.79
Current: -4.1

During the past 12 years, the highest Debt-to-EBITDA Ratio of Biosolution Co was 34.79. The lowest was -11.34. And the median was 4.34.

XKRX:086820's Debt-to-EBITDA is ranked worse than
100% of 272 companies
in the Biotechnology industry
Industry Median: 1.375 vs XKRX:086820: -4.10

Biosolution Co Debt-to-EBITDA Historical Data

The historical data trend for Biosolution Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosolution Co Debt-to-EBITDA Chart

Biosolution Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.79 24.43 -11.34 7.83 -4.10

Biosolution Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.74 -4.36 13.43 -4.72 -1.73

Competitive Comparison of Biosolution Co's Debt-to-EBITDA

For the Biotechnology subindustry, Biosolution Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosolution Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biosolution Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biosolution Co's Debt-to-EBITDA falls into.


;
;

Biosolution Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Biosolution Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(27268.08 + 970.606) / -6887.301
=-4.10

Biosolution Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(27268.08 + 970.606) / -16363.632
=-1.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Biosolution Co  (XKRX:086820) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Biosolution Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Biosolution Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosolution Co Business Description

Traded in Other Exchanges
N/A
Address
Gongneung-Ro 232, Nowon-gu, 5th Floor, Room 519, Seoul Technopark, Seoul, KOR
Biosolution Co Ltd is a Korean company offering Cell-Based Biotechnology. It is engaged in manufacturing and selling cell therapy products, and developing cell therapeutics technology. Its main areas include cell-based therapeutics with their background in somatic and stem cell technology, and the manufacturing, sales, and R&D of human tissue models for screening toxicity and efficacy with tissue engineering technology.

Biosolution Co Headlines

No Headlines